The TME, particularly in HR+ and HER2+ breast cancers, often features an immunosuppressive landscape, which contributes to therapeutic resistance and necessitates innovative strategies to reprogram the immune milieu. This evidence concerns the gene ERBB2 and breast carcinoma.